Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome™ Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.
Title: One Year Results of a Phase 1 Study Evaluating the Safety and Evidence of Efficacy of a Single Intravitreal Injection of the Verisome™ Liquid Drug Delivery System for Sustained Release of Low-Dose Triamcinolone (IBI-20089) in Eyes With Cystoid Macular Edema
Program Number: 6396
Session Date/Time: Thursday, May 6, 2010 from 1:15-3:00pm; Room Grand H
Session Title: Macular Edema – Clinical Trials
New treatment targeting aging cells could offer lasting relief for diabetic macular edema